CoALL 2020 Registry

The registry is intended to collect disease- and person-specific data of children and adolescents with ALL or T-/B-precursor NHL who are diagnosed and treated in the trial centres of the former CoALL 08-09 study. Data concerning the biology and the development of the disease are of special interest.

Objectives

• Recording of all ALL as well as T- and B-precursor NHL diseases and their treatment in children and adolescents in the participating centres.
• Recording of the morphological, cytogenetic, molecular genetic as well as immunophenotypic characteristics of ALL and T-/B-precursor NHL in children at the initial diagnosis and in the course of therapy.
• Recording of the treatment response by minimal residual disease (MRD) during the course of therapy.
• Recording the frequency of (molecular) relapse.
• Determination of the overall survival and event-free survival.
• Analysis of the influence of MRD-based risk classification and therapeutical decisions on overall survival and event-free survival in a historical comparison.

The registry does not provide any specific therapy recommendations. Patients should be treated according to an established German standard therapy. The study coordination centre is giving advice on individual therapy strategies in individual cases.

• Primary acute lymphoblastic leukaemia (ALL) or
• ALL as a second malignancy or
• Acute biphenotypical leukaemia (after consultation and approval by the Study coordination centre) or
• Acute undifferentiated leukaemia (after consultation and approval by the Study coordination centre) or
• Non-Hodgkin Lymphomas: T-NHL or B-precursor-NHL, if there is no participation in the LBL 2018 study or
• "Special“ cases of ALL-associated diseases (after consultation and approval by the Study coordination centre) or
• ALL relapse without participation in one of the IntReALL studies
• Age at diagnosis < 18 or >= 18 (after consultation and approval by the Study coordination centre
• Admission to an accredited paediatric oncology centre in accordance with the GBA decision "Paediatric Oncology"
• Consent of the patient and legal representative

• Missing consent of the patient and/or the legal representative
• Patient with primary ALL with Philadelphia-Chromosome (BCR/ABL)